

# Julio C Rojas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3021913/publications.pdf>

Version: 2024-02-01

31  
papers

3,304  
citations

430754

18  
h-index

477173

29  
g-index

32  
all docs

32  
docs citations

32  
times ranked

5095  
citing authors

#	ARTICLE	IF	CITATIONS
1	ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. <i>Nature</i> , 2017, 549, 523-527.	13.7	852
2	Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. <i>Nature Medicine</i> , 2020, 26, 387-397.	15.2	471
3	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. <i>JAMA Neurology</i> , 2019, 76, 1035.	4.5	455
4	Prospective longitudinal atrophy in Alzheimer's disease correlates with the intensity and topography of baseline tau-PET. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	353
5	Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. <i>Lancet Neurology</i> , The, 2021, 20, 739-752.	4.9	220
6	Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. <i>Annals of Clinical and Translational Neurology</i> , 2016, 3, 216-225.	1.7	163
7	4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration. <i>Acta Neuropathologica</i> , 2020, 139, 63-77.	3.9	89
8	Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease. <i>Neurology</i> , 2021, 96, e671-e683.	1.5	84
9	Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome. <i>JAMA Neurology</i> , 2020, 77, 215.	4.5	81
10	CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. <i>Neurology</i> , 2018, 90, e273-e281.	1.5	75
11	Promoting tau secretion and propagation by hyperactive p300/CBP via autophagy-lysosomal pathway in tauopathy. <i>Molecular Neurodegeneration</i> , 2020, 15, 2.	4.4	69
12	Association of Blood and Cerebrospinal Fluid Tau Level and Other Biomarkers With Survival Time in Sporadic Creutzfeldt-Jakob Disease. <i>JAMA Neurology</i> , 2019, 76, 969.	4.5	65
13	Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. <i>Neurology</i> , 2021, 96, e2296-e2312.	1.5	52
14	Plasma Glial Fibrillary Acidic Protein Levels Differ Along the Spectra of Amyloid Burden and Clinical Disease Stage1. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 265-276.	1.2	43
15	Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1250-1263.	1.7	40
16	<sc>OpenLabel</sc> Phase 1 Futility Studies of Salsalate and Young Plasma in Progressive Supranuclear Palsy. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 440-447.	0.8	34
17	Four-Repeat Tauopathies: Current Management and Future Treatments. <i>Neurotherapeutics</i> , 2020, 17, 1563-1581.	2.1	24
18	Targeting tauopathies for therapeutic translation. <i>Nature Reviews Neurology</i> , 2016, 12, 74-76.	4.9	21

#	ARTICLE	IF	CITATIONS
19	Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTLD spectrum disorders. <i>Cell Reports Medicine</i> , 2022, 3, 100607.	3.3	21
20	Effect of the Histone Deacetylase Inhibitor FRM-0334 on Progranulin Levels in Patients With Progranulin Gene Haploinsufficiency. <i>JAMA Network Open</i> , 2021, 4, e2125584.	2.8	18
21	Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration. <i>JAMA Network Open</i> , 2022, 5, e229588.	2.8	18
22	Lower White Matter Volume and Worse Executive Functioning Reflected in Higher Levels of Plasma GFAP among Older Adults with and Without Cognitive Impairment. <i>Journal of the International Neuropsychological Society</i> , 2022, 28, 588-599.	1.2	14
23	Genetic Prion Disease Caused by PRNP Q160X Mutation Presenting with an Orbitofrontal Syndrome, Cyclic Diarrhea, and Peripheral Neuropathy. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 249-258.	1.2	13
24	Plasma P-tau181 and P-tau217 in Patients With Traumatic Encephalopathy Syndrome With and Without Evidence of Alzheimer Disease Pathology. <i>Neurology</i> , 2022, 99, .	1.5	10
25	Peripheral Innate Immune Activation Correlates With Disease Severity in GRN Haploinsufficiency. <i>Frontiers in Neurology</i> , 2019, 10, 1004.	1.1	7
26	Selective vulnerability to atrophy in sporadic Creutzfeldt-Jakob disease. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1183-1199.	1.7	4
27	Multiproteinopathy, neurodegeneration and old age: a case study. <i>Neurocase</i> , 2018, 24, 1-6.	0.2	2
28	Visual Impairment as a Modifiable Risk Factor in Dementia Prevention and Management. <i>JAMA Neurology</i> , 2022, 79, 542.	4.5	2
29	Non-amnesic mild cognitive impairment. , 2016, , 232-244.		1
30	NEUROFILAMENT LIGHT CHAIN AS A BIOMARKER FOR FRONTOTEMPORAL LOBAR DEGENERATION. <i>Alzheimer's and Dementia</i> , 2018, 14, P603.	0.4	0
31	Sensitivity of the Social Behavior Observer Checklist to Early Symptoms of Patients With Frontotemporal Dementia. <i>Neurology</i> , 2022, , 10.1212/WNL.0000000000200582.	1.5	0